Related by context. All words. (Click for frequent words.) 75 EGFR inhibitors 74 imatinib Gleevec 73 tyrosine kinase inhibitor 72 proteasome inhibitors 72 dasatinib Sprycel 72 TKIs 71 erlotinib Tarceva ® 71 molecularly targeted 70 T#I mutation 70 imatinib Gleevec ® 70 anticancer agents 70 gefitinib Iressa 70 dasatinib 70 tyrosine kinase inhibitors TKIs 69 chemotherapeutic agents 69 receptor tyrosine kinase inhibitor 69 MEK inhibitors 69 nilotinib 69 EGFr 69 pertuzumab 69 taxanes 69 VEGF inhibitors 68 imatinib 68 HDAC inhibitors 68 mTOR inhibitors 68 proteasome inhibitor 68 insulin sensitizers 68 idarubicin 68 anti angiogenic drugs 68 cetuximab Erbitux ® 68 nucleoside analogues 68 anticancer therapies 68 PARP inhibitors 67 calcineurin inhibitors 67 histone deacetylases 67 cediranib 67 bevacizumab Avastin ® 67 MMP inhibitors 67 NNRTIs 67 IGF 1R 67 anti angiogenic agents 67 anthracyclines 67 dasatinib Sprycel ® 67 standard chemotherapy regimens 67 predictive biomarkers 67 vinca alkaloid 67 thalidomide Thalomid 66 gemcitabine Gemzar 66 Xanafide 66 CYT# potent vascular disrupting 66 EGFR tyrosine kinase inhibitors 66 anti TNF 66 erlotinib Tarceva 66 nilotinib Tasigna 66 chemotherapeutics 66 nilotinib Tasigna ® 66 imatinib resistant 66 Gleevec resistant 66 EGFR pathway 66 epithelial tumors 66 sorafenib Nexavar 66 EGFR mutations 66 cetuximab Erbitux R 66 alkylating agents 66 histone deacetylase inhibitors 66 mTOR inhibitor 66 BRAF mutation 66 HCV protease 66 kinase inhibitors 66 multitargeted 66 angiogenesis inhibitor 66 immunomodulatory 65 temsirolimus 65 cytotoxic chemotherapy 65 BCR ABL 65 nucleoside analogs 65 bortezomib 65 Trastuzumab 65 SERMs 65 TNF inhibitors 65 T#I [002] 65 chemotherapeutic agent 65 lupus nephritis 65 Dasatinib 65 DMARDs 65 small molecule inhibitors 65 bevacizumab Avastin 65 CCR5 antagonists 65 cytotoxic agents 65 antisense oligonucleotides 65 vinca alkaloids 65 paclitaxel Taxol 65 FLT3 65 anti mitotic 65 AMN# [001] 65 immunomodulator 65 vascular disrupting agents 65 BRAF inhibitor 65 protease inhibitors 65 pancreatic adenocarcinoma 65 CCR5 antagonist 65 chemotherapies 65 chemotherapy regimens 65 TKI therapy 65 pan HDAC inhibitor 65 metastatic RCC 65 disease modifying antirheumatic 65 visilizumab 64 imatinib mesylate Gleevec 64 HER2 positive metastatic breast 64 imatinib resistance 64 chemotherapeutic drugs 64 JAK#/JAK# 64 Bortezomib 64 HGS# 64 JAK inhibitors 64 lapatinib Tykerb 64 HSP# inhibitor 64 Imatinib 64 HDACi 64 Ceflatonin 64 Sorafenib Nexavar 64 CBLC# 64 mycophenolate mofetil 64 Zolinza 64 EGFR TKIs 64 mRCC 64 trabectedin 64 EGFR 64 EGF receptor 64 bortezomib Velcade 64 taxane therapy 64 metastatic renal cell carcinoma 64 docetaxel Taxotere ® 64 Pertuzumab 64 OXi# 64 leukemia AML 64 CD# antibodies 64 Herceptin trastuzumab 64 ixabepilone 64 somatostatin analogue 64 vascular disrupting agent 64 gefitinib 64 hematological cancers 64 Gefitinib 64 myelofibrosis polycythemia vera 64 integrase inhibitors 64 gastrointestinal stromal tumors 64 PDGF receptor 64 Alemtuzumab 64 K ras mutations 64 HuLuc# 64 kinase inhibitor 64 biologic therapy 64 hedgehog pathway 64 TACE 64 NRTIs 64 Fludarabine 64 chemotherapeutic drug 64 infliximab Remicade 63 decitabine 63 gastrointestinal stromal tumors GIST 63 fulvestrant 63 BCR ABL inhibitors 63 HDACs 63 multi kinase inhibitor 63 interferon IFN 63 chemotherapeutic 63 gemcitabine 63 erlotinib 63 leukemia CLL 63 cisplatin resistant 63 androgen independent 63 Tyrima 63 Hedgehog pathway 63 tyrosine kinase inhibitor TKI 63 Doxil ® 63 topotecan 63 liposomal doxorubicin 63 relapsed SCLC 63 AEG# 63 EGFR TKI 63 docetaxel chemotherapy 63 selective inhibitors 63 breast cancer subtypes 63 signal transduction inhibitor 63 pegfilgrastim 63 cancer immunotherapies 63 alkylating agent 63 Symadex 63 tyrosine kinases 63 anticancer therapy 63 imatinib therapy 63 PI3K/mTOR 63 protein kinase inhibitor 63 trastuzumab Herceptin 63 ALK inhibitors 63 Gleevec imatinib mesylate 63 Hsp# inhibitors 63 metaglidasen 63 BRAF gene 63 epigenetic therapies 63 IAP inhibitors 63 chronic lymphocytic leukemia CLL 63 angiogenesis inhibitors 63 trans retinoic acid ATRA 63 mutational status 63 hematologic malignancies 63 Fludara ® 63 metastatic colorectal cancer 63 OncoVEX GM CSF 63 trastuzumab 63 etoposide 63 antihypertensive agents 63 ErbB3 HER3 63 IAP inhibitor 63 epothilones 63 VEGFR2 63 PKC# 63 rituximab 63 antithrombotic 63 sodium glucose cotransporter 63 sunitinib Sutent ® 63 azoles 63 echinocandins 63 epothilone 63 PARP inhibitor 63 VEGF receptor 63 induce apoptosis 63 enzastaurin 63 gamma secretase inhibitors 63 antiangiogenic 63 heavily pretreated patients 63 NF kB pathway 63 deacetylase inhibitors 63 Vidaza ® 63 WT1 62 chronic myeloid leukemia CML 62 anti angiogenic 62 PI3K Akt 62 histologies 62 humanized antibody 62 IgG1 antibody 62 standard chemotherapy regimen 62 Notch1 62 anti VEGF 62 temozolomide 62 CYC# 62 doxorubicin 62 kinase inhibition 62 HGS ETR1 62 BRAF inhibitors 62 polymerase inhibitors 62 flavopiridol 62 Bevacizumab 62 Abl 62 targeting CD# 62 relapsed ovarian cancer 62 cell malignancies 62 pegylated liposomal doxorubicin 62 HER2 receptor 62 T#I mutant 62 exemestane Aromasin 62 obatoclax 62 VEGF receptors 62 Campath alemtuzumab 62 chemotherapeutic regimens 62 immune modulating 62 preclinically 62 gemcitabine Gemzar ® 62 BCR ABL mutations 62 immunosuppressant 62 ENMD # 62 costimulatory 62 NEUGENE 62 elacytarabine 62 metastatic malignant melanoma 62 heavily pretreated 62 BAY #-# 62 taxane chemotherapy 62 Src inhibitors 62 gastrointestinal stromal tumor GIST 62 Smac mimetic 62 immunomodulatory therapy 62 Taxanes 62 uric acid lowering 62 UsiRNAs 62 Erlotinib 62 DMARDS 62 endocrine therapies 62 Telintra 62 cilengitide 62 vorinostat 62 pro angiogenic 62 PLX# 62 LHRH 62 delta isoform 62 EGFR HER2 62 Tarceva erlotinib 62 xenograft models 62 taxane 62 EGFR mutation 62 Targretin 62 PI3 kinase 62 rifamycins 62 Hedgehog signaling pathway 62 disease modifying 62 PDGFR 62 superficial bladder cancer 62 olaparib 62 TNF alpha inhibitors 62 JAK1 62 antiangiogenesis 62 resistant ovarian cancer 62 renin inhibitors 62 orally administered inhibitor 62 ganetespib 62 immunosuppressive agents 62 FGFR1 62 demethylating agents 62 metastatic colorectal 62 solid tumors 62 selectively inhibit 62 bendamustine 62 gamma secretase inhibitor 62 interferon alfa 62 liposomal formulation 62 cetuximab 62 inhibit EGFR 62 TNF inhibitor 62 tocilizumab 62 docetaxel Taxotere 62 predictive biomarker 62 Fludara 62 Preclinical studies suggest 62 direct thrombin inhibitors 62 JAK3 62 TriRima 62 GIST tumors 62 histone deacetylase HDAC inhibitors 62 anti angiogenic therapy 62 YONDELIS 62 OHR/AVR# 62 Epothilones 62 protein kinases 62 DMARD 62 Epidermal Growth Factor Receptor 62 anticancer drugs 62 lenalidomide Revlimid R 62 proto oncogene 62 immunomodulating 62 histone deacetylase HDAC 62 nucleoside analogue 62 EGFR antibodies 61 bosutinib 61 panitumumab Vectibix 61 taxol 61 cell lymphoma CTCL 61 chlorambucil 61 tumor suppressors 61 apoptotic pathway 61 potent inhibitors 61 Panzem R NCD 61 ALK inhibitor 61 5 HT3 receptor 61 immunosuppressive 61 triptans 61 Irinotecan 61 FOLFIRI 61 demethylating agent 61 selective inhibitor 61 GRN#L 61 HDAC 61 interferons 61 endothelin receptor antagonists 61 MEK inhibitor 61 PXD# 61 Enbrel Humira 61 CCX# 61 hypomethylating agents 61 recurrent NSCLC 61 ADP receptor antagonist 61 PNP inhibitor 61 bleomycin 61 sapacitabine 61 Temsirolimus 61 Cytoxan 61 TREANDA 61 DFMO 61 exon skipping 61 Velcade bortezomib 61 anthracycline containing 61 dacarbazine 61 Pemetrexed 61 ErbB3 61 Everolimus 61 castration resistant prostate cancer 61 azacytidine 61 docetaxel Taxotere R 61 small molecule tyrosine 61 humanised monoclonal antibody 61 KRAS mutations 61 pomalidomide 61 JAK2 inhibitors 61 investigational therapies 61 HER2 overexpression 61 Omacetaxine mepesuccinate 61 Hsp# inhibition 61 hypereosinophilic syndrome 61 humanized monoclonal antibody 61 Interferon alpha 61 vemurafenib 61 panobinostat 61 receptor antagonists 61 antitumor 61 TELINTRA 61 Vidofludimus 61 bevacizumab Avastin R 61 sorafenib 61 KIT mutations 61 Neuvenge 61 VEGF pathway 61 VAPRISOL 61 signal transduction inhibitors 61 myeloid 61 raltegravir 61 c MET 61 CCR2 61 JAK2 61 chronic myelogenous leukemia CML 61 endoxifen 61 LY# [003] 61 talabostat 61 multikinase inhibitor 61 TLR9 agonist 61 myeloproliferative disorders 61 HCV protease inhibitors 61 druggable targets 61 cetuximab Erbitux 61 CA4P 61 inhibiting tumor 61 peripherally acting 61 Smac mimetics 61 dexamethasone Decadron 61 APOPTONE 61 IMA# 61 TELCYTA 61 azacitidine 61 TNFa 61 trans retinoic acid 61 LHRH agonists 61 myeloma cells 61 rituximab Rituxan 61 Traficet EN 61 brostallicin 61 myeloproliferative diseases 61 anti angiogenic agent 61 NSCLC 61 follicular lymphoma 61 metastatic malignant 61 MGd 61 anti TNF alpha 61 cutaneous T 61 carboplatin paclitaxel 61 PI3K 61 Sorafenib 61 TRAIL induced apoptosis 61 substrates inhibitors 61 KRAS oncogene 61 B CLL 61 seliciclib 61 B7 H3 61 bexarotene 61 Torisel 61 Clofarabine 61 anti leukemic 61 malignancies 61 imatinib mesylate 61 NFkB 60 antiproliferative effects 60 selective kinase inhibitor 60 tafamidis 60 TNFα 60 anticancer agent 60 Factor Receptor 60 protein tyrosine phosphatase 1B 60 Carfilzomib 60 familial amyloidotic polyneuropathy FAP 60 MAGE A3 ASCI 60 therapeutic regimens 60 BRAF mutations 60 interleukins 60 SCCHN 60 chimeric monoclonal antibody 60 Epratuzumab 60 Bcr Abl mutations 60 PI3K inhibitors 60 ponatinib 60 novel anticancer 60 daunorubicin 60 Novartis Gleevec 60 adriamycin 60 recurrent GBM 60 tyrosine kinase 60 pDCs 60 xanthine oxidase inhibitor 60 recurrent glioblastoma multiforme 60 TNF antagonists 60 Janus kinase 60 pegylated interferons 60 metastatic CRC 60 Gleevec imatinib 60 selective inhibition 60 chronic eosinophilic leukemia 60 antiangiogenic therapy 60 essential thrombocythemia 60 luteinizing hormone releasing 60 investigational humanized monoclonal antibody 60 castrate resistant prostate cancer 60 cytostatic 60 recurrent glioblastoma 60 androgen receptor AR 60 mapatumumab 60 M2 subunit 60 fibrinolytic 60 fludarabine 60 targeted antifolate 60 oblimersen 60 gastrointestinal stromal tumors GISTs 60 regorafenib 60 Gleevec 60 HDAC6 60 Tumor Necrosis Factor 60 endostatin 60 refractory chronic myeloid 60 nucleoside analog 60 Aflibercept 60 depsipeptide 60 chemoresistance 60 Aurora kinases 60 alkylating 60 interferon 60 Gemzar ® 60 bicalutamide 60 reverse transcriptase inhibitors 60 SGLT 2 60 anti angiogenesis 60 antimitotic 60 GW# [003] 60 Bcr Abl inhibitors 60 cellular pathways 60 Voreloxin 60 peroxisome proliferator activated 60 myelodysplastic syndrome MDS 60 interferon alpha 60 Hedgehog inhibitor 60 Curaxins 60 dexpramipexole 60 trastuzumab Herceptin ® 60 FGFR 60 kidney urologic 60 Nexavar ® 60 pimozide 60 Rituximab 60 Apo2L 60 immune modulators 60 neuroprotectant 60 sorafenib Nexavar ® 60 CXCR4 receptor 60 CORT # 60 fluoropyrimidine 60 Taxol ® 60 docetaxel 60 leukemic stem cells 60 malignant pleural mesothelioma 60 immunotherapeutic agent 60 Hodgkin lymphoma NHL 60 Aurora kinase 60 histone deacetylase HDAC inhibitor 60 cisplatin 60 anti EGFR antibody 60 aminoglycosides 60 EpCAM 60 antisense oligonucleotide 60 sunitinib malate 60 castrate resistant 60 Doxorubicin 60 Cisplatin 60 antibody MAb 60 nucleosides 60 ERBB2 60 G CSF 60 LHRH antagonists 60 GRASPA ® 60 T DM1 60 Amigal 60 antiangiogenesis therapies 60 NS5A 60 SARMs 60 antimetabolite 60 PDE4 inhibitors 60 anticancer treatments 60 acute leukemias 60 NS4A 60 PEGylated Fab fragment 60 MGCD# [001] 60 orally bioavailable 60 HRPC 60 BRCA deficient 60 OMP #M# 60 neurotrophic 60 IGFBP2 60 Nexavar sorafenib 60 MyVax R 60 CHOP chemotherapy 60 retinoids 60 protein kinase inhibitors 60 receptor agonists 60 modulates Akt 60 Vidaza R 60 SUTENT 60 small molecule activators 60 adalimumab Humira 60 IFN alpha 60 Talabostat 60 cytoprotective 60 IMC A# 60 echinocandin 60 Aplidin 60 oncoproteins 60 Blinatumomab 60 refractory NSCLC 60 HER3 60 nucleoside reverse transcriptase inhibitor 60 peptide antigens 60 liver metastases 60 personalized immunotherapy 60 anti fibrotic 60 Onconase 60 vinorelbine 60 Elotuzumab 60 CDK inhibitor 60 Bcr Abl 60 non squamous 60 cytarabine 60 follicular NHL 60 Protein Kinase C 60 interferon therapy 60 ErbB2 60 IgG1 monoclonal antibody 60 biologic therapies 60 DEB# 60 Deforolimus 60 thyroid hormone receptor 60 intravenous cyclophosphamide 60 Imprime PGG 60 tubulin binding 60 neuroendocrine cancers 59 signaling cascades 59 sunitinib Sutent 59 aromatase inhibitors 59 potent anticancer 59 neuropilin 59 CCR5 inhibitors 59 EGFR inhibitor 59 immunosuppressive therapies 59 multiple myeloma MM 59 PIK3CA 59 novel peptide 59 DXL# 59 lymphoid malignancies 59 Amrubicin 59 XmAb# 59 DAPT 59 tumor vasculature 59 DHFR 59 Factor VIIa 59 CCR5 inhibitor 59 medulloblastoma 59 selective modulator 59 multidrug resistance 59 Ph + ALL 59 NSCLC tumors 59 PI3K inhibitor 59 receptor inhibitor 59 acute myelogenous leukemia AML 59 chemoresistant 59 humanized anti 59 oxidative stress inducer 59 peritoneal carcinomatosis 59 lipid lowering therapies 59 Anthracycline 59 indolent NHL 59 adjuvant therapy 59 TNF alpha blockers 59 GPCRs 59 protein mTOR 59 HCV nucleoside 59 anthracycline 59 glioblastoma 59 aromatase inhibitor 59 diagnostic biomarker 59 cardiotoxic 59 mutated KRAS gene 59 reversible inhibitors 59 rhIL 7 59 potent inhibitor 59 CTLA 4 59 basal cell carcinoma BCC 59 entinostat 59 gemcitabine carboplatin 59 Kinase inhibitors 59 Dapagliflozin 59 mitochondrial toxicity 59 KRAS mutation 59 alpha folate receptor 59 microtubule targeting 59 5 Fluorouracil 59 cathepsins 59 TLR8 59 small molecule defensin 59 Genentech Herceptin 59 VitiGam 59 prostate carcinoma 59 immune modulator 59 basiliximab 59 etanercept Enbrel 59 macrolide antibiotics 59 Nanobodies 59 Ofatumumab 59 TG# [003] 59 refractory AML 59 chemotherapeutic regimen 59 cytotoxic 59 Protease inhibitors 59 histone deacetylase inhibitor 59 PPARgamma 59 endothelin receptor 59 galiximab 59 APTIVUS r 59 octreotide 59 vWF 59 tigecycline 59 MUC1 59 liver metastasis 59 GPCR targets 59 inhibitor RG# 59 anti TNFs 59 STAT3 59 serine protease 59 irinotecan chemotherapy 59 potent antiproliferative 59 Enzastaurin 59 TLR agonists 59 PI3K/Akt pathway inhibitor 59 panitumumab 59 VDAs 59 Revlimid lenalidomide 59 differentiated thyroid 59 cholinesterase inhibitors 59 tarenflurbil 59 beta interferon 59 PD# [005] 59 COX2 59 polycythemia vera PV 59 protease inhibitor 59 HDAC inhibition 59 leukemia ALL 59 adecatumumab 59 doxorubicin Adriamycin 59 sunitinib 59 TNF α 59 immunotherapies 59 neoadjuvant chemotherapy 59 elotuzumab 59 miR #a [002] 59 abiraterone 59 infliximab 59 TLR9 agonists 59 letrozole Femara 59 novel VDA molecule 59 Thiarabine 59 platinum refractory 59 TRIOLEX 59 poly ADP ribose polymerase 59 hormone refractory prostate cancer 59 tumor antigens 59 NKT cells 59 selectively inhibited 59 amrubicin 59 drug zotarolimus 59 Tarvacin 59 BMS # 59 teriflunomide 59 NKG2D 59 TLK# 59 PRT# 59 Chronic Lymphocytic Leukemia CLL 59 Factor Xa 59 axitinib 59 Cloretazine 59 SCH # 59 prostate cancer HRPC 59 Doxil 59 ZOLINZA 59 receptors EGFR 59 FGFR2 59 SPRYCEL ® 59 radiation sensitizer 59 topoisomerase 59 KRAS wild 59 SGLT2 inhibitors 59 angiogenesis inhibition 59 alefacept 59 PROCHYMAL 59 stage IIIB 59 monoclonal antibody therapies 59 factor Xa 59 ALN TTR 59 epirubicin 59 paclitaxel Taxol ® 59 PPARγ 59 glucocorticoid receptor 59 metastatic colon cancer 59 Kantarjian 59 chemopreventive agent 59 CD# antibody [001] 59 metastatic kidney 59 oncogenes 59 SIRT2 59 ZD# [001] 59 MAPK pathway 59 5 fluorouracil leucovorin 59 vandetanib 59 tumor suppressor genes 59 TRAIL receptor antibodies 59 modulators SERMs 59 ON #.Na 59 thrombopoietin 59 AVI NEUGENE 59 erythropoietic 59 Hepatocellular Carcinoma HCC 59 microtubule inhibitor 59 5alpha reductase 59 Squalamine 59 ERK pathway 59 ACE angiotensin converting enzyme 59 Omacetaxine 59 trastuzumab Herceptin R 59 CDKs 59 cisplatin chemotherapy 59 HQK 59 integrase inhibitor 59 pediatric acute lymphoblastic 59 reversible inhibitor 59 systemic ALCL 59 mTOR mammalian target 59 phosphate S1P 59 vaccines oncolytic virus 59 beta adrenergic 59 Skp2 59 HGS ETR2 59 Rituxan rituximab 59 coagulation cascade 59 ERK signaling 59 ErbB 59 immunomodulation 59 hormone LHRH 59 assessing T DM1 59 chemopreventive agents 59 Maraviroc 59 MEK1 59 LHRH receptor positive 59 Stat5 59 Annamycin 59 CRAC channel 59 Romidepsin 59 metastatic castration resistant 59 enzyme inhibitors 59 tanespimycin 59 camptothecin 59 VEGF inhibitor 59 GVHD 59 immune stimulatory 59 CD3 monoclonal antibody 59 angiotensin converting enzyme inhibitors 59 LNP formulations 59 pharmacologic agents 59 intracellular pathways 59 lenalidomide dexamethasone 59 sorafenib tablets 59 oxaliplatin 59 glitazones 59 GSK3 58 adoptive immunotherapy 58 anticholinergics 58 antiangiogenic agents 58 Aliskiren 58 TTR gene 58 PARP inhibition 58 LEUKINE 58 tricyclics 58 DNA methyltransferases 58 5 lipoxygenase 58 pazopanib 58 oral anticancer 58 thrombin receptor 58 Pegasys ® 58 refractory metastatic 58 IMiDs 58 tumor subtypes 58 cisplatin carboplatin 58 Her2 58 LHRH analogues 58 HBeAg positive patients 58 antiangiogenic activity 58 conventional chemotherapies 58 radezolid 58 Taxotere ® 58 p# MAP kinase 58 TNF Tumor Necrosis Factor 58 DACH platinum 58 VIPR2 58 Beta catenin pathway 58 leukemic cell 58 antihypertensive drugs 58 factor TNF 58 beta lactams 58 photodynamic therapy 58 unresectable 58 receptor modulators 58 IGF1R 58 VEGFR 58 TOP2A 58 MET amplification 58 mTOR pathway 58 GISTs 58 CDDO Im 58 protein tyrosine phosphatases 58 tyrosine kinase receptor 58 thiazolidinediones 58 cMET 58 chemosensitivity 58 motesanib 58 anthracycline taxane 58 resectable 58 LY# [002] 58 5 FU leucovorin 58 prescribed proton pump 58 lymphomas 58 p# inhibitors 58 pemetrexed Alimta 58 Dalbavancin 58 pro apoptotic 58 Monoclonal antibodies 58 angiotensin receptor blockers ARBs 58 Clusterin 58 cyclosporin 58 gemcitabine cisplatin 58 advanced NSCLC 58 Paraplatin ® 58 incretin 58 YONDELIS R 58 MPS IVA 58 selective estrogen receptor 58 cell signaling pathways 58 BRAF kinase 58 mitotic kinesins 58 cutaneous T cell 58 antiestrogen 58 CRTH2 58 prognostic markers 58 virotherapy 58 FK# 58 acadesine 58 immunosuppressive regimens 58 GBM tumors 58 AZD# 58 Panzem NCD 58 molecular biomarkers 58 Vidaza azacitidine 58 small molecule inhibitor 58 calcineurin 58 quinolones 58 DCVax R 58 Perifosine 58 Intravenous CP 58 siRNA therapeutics 58 Panzem R 58 irinotecan doxorubicin oxaliplatin paclitaxel 58 antiepileptics 58 Sphingomab 58 efavirenz Sustiva 58 Ozarelix 58 OMAPRO 58 antiangiogenic drugs 58 serotonin receptor 58 BCR ABL protein 58 resolvins